Piper Sandler analyst Joseph M. Catanzaro reiterated an Overweight rating and $40.00 price target on Day One Biopharmaceuticals (NASDAQ: DAWN).The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE